Top Markets
#1 Akedo Akedo +69.97%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.06%
#4 Cross Cross +36.90%
#5 Velvet Velvet +31.95%
#6 Black Phoenix Black Phoenix +26.64%
#7 Cap Cap +22.61%
#8 OVERTAKE OVERTAKE +19.97%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.79%
#10 Ontology Gas Ontology Gas +11.65%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
H-CYTE, Inc. H-CYTE, Inc.

H-CYTE, Inc.

HCYT
Rank in Stocks #39159
H-CYTE, Inc. is a biopharmaceutical firm based in the United States, dedicated... H-CYTE, Inc. is a biopharmaceutical firm based in the United States, dedicated to developing and supplying a range of treatments for individuals afflicted with persistent respiratory and pulmonary diseases. The company's core strategy involves pioneering and deploying autologous cellular therapy solutions specifically for chronic lung conditions. Additionally, H-CYTE maintains a product supply agreement with Rion, LLC, focused on advancing and distributing a biologic compound designed to combat chronic obstructive pulmonary disease (COPD). Its corporate headquarters are situated in Tampa, Florida.
Share Price
$0.995
Last synced: 2023-07-07
Market Cap
$624.98K
Change (1 day)
-0.50%
Change (1 year)
0.00%
Country
US
Trade H-CYTE, Inc. (HCYT)

Category

Healthcare
Revenue for H-CYTE, Inc. (HCYT)
Revenue in Aug 2026 TTM: 0
According to H-CYTE, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for H-CYTE, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE